Could this therapy help save infant lives?

Share:
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale

This article is published in collaboration with YaleNews.

The majority of infants with the rare disease known as GACI (generalized arterial calcification of infancy) die within the first year of life. Now Yale scientists have developed and tested a therapy that not only targets the underlying cause of GACI but also eliminates mortality in rodent models of the human disease.

The research, led by associate professor of pathology Dr. Demetrios Braddock, was published Dec. 1 in Nature Communications.

Infant patients with GACI have arterial “calcifications,” or abnormal buildup of calcium in blood vessels. The calcifications cause hardening of arteries, heart failure, and death in most cases. Treatment for GACI is currently limited to an intensive therapy that is minimally effective.

In their study, Braddock and his colleagues focused on an important yet poorly understood enzyme, ENPP1, which is impaired in GACI patients. The researchers injected GACI mice with daily doses of an ENPP1 therapy. They demonstrated that the therapy eliminated the calcifications as well as related heart disease and mortality.

“We show that the therapy is curative in GACI — there is no calcification and no death,” said Braddock. “The key finding is that this lethal disease can be prevented with daily injections of this protein.”

The next step, now that the therapy has been shown to be effective in preventing calcifications associated with the disease, noted Braddock, is to test whether the therapy can reduce or eliminate calcifications in other animal models. The ultimate goal of the research team is to test the therapy in humans with GACI.

These findings are likely to have applications in other severe clinical conditions, he said. “We believe that we can propose treating patients in renal failure suffering from vascular calcification with this therapy,” Braddock noted. “We are optimistic that we will see a response.”

Publication does not imply endorsement of views by the World Economic Forum.

To keep up with the Agenda subscribe to our weekly newsletter.

Author: Ziba Kashef is a Senior Writer, Editor and Communications Consultant helping businesses and organisations reach strategic goals.

Image: A nurse poses for a photo in a trauma center of the University of Mississippi Medical Center in Jackson, Mississippi October 4, 2013. REUTERS/Jonathan Bachman.

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

About us

Engage with us

  • Sign in
  • Partner with us
  • Become a member
  • Sign up for our press releases
  • Subscribe to our newsletters
  • Contact us

Quick links

Language editions

Privacy Policy & Terms of Service

Sitemap

© 2024 World Economic Forum